Jefferies reiterates Buy rating on Structure Therapeutics stock after GLP1 data

Investing.com - Jefferies maintained its Buy rating and $79.00 price target on Structure Therapeutics (NASDAQ:GPCR) following the company’s Phase 2b data for its small molecule GLP1 receptor agonist, aleniglipron. Structure Therapeutics, currently trading at $69.45 with a market cap of $2.1 billion, has seen impressive gains with a 63.56% price return over the past six months.

The firm highlighted "solid" clinical results from the ACCESS and ACCESS II trials, describing aleniglipron as having "best-in-class efficacy among oral incretins" with a "Phase 3 ready" profile and "second to market potential." This positive outlook aligns with the broader analyst consensus, which remains strongly bullish with a 1.23 rating (where 1 is Strong Buy), and price targets ranging from $44 to $120.

Structure Therapeutics also provided initial data from the ACCESS open-label extension study and an ongoing Phase 2 body composition study, with Jefferies noting the company has a "clear strategy to further improve GI tolerability" for the drug.

The company plans to proceed with end-of-Phase 2 meetings in the first half of 2026 and initiate Phase 3 trials in early second half of 2026, according to Jefferies’ research note.

Multiple catalysts are expected in 2026 from both the aleniglipron program and the company’s amylin program, with Jefferies concluding the topline data "reinforces a Phase 3 ready profile with best-in-class weight loss, along with clean safety and acceptable/further improvable GI tolerability." Interestingly, InvestingPro data shows the stock often moves opposite to the market with a beta of -1.75, potentially offering portfolio diversification. For deeper insights on Structure Therapeutics and access to its comprehensive Pro Research Report, consider exploring InvestingPro.

In other recent news, Structure Therapeutics announced positive results from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist aimed at obesity treatment. The Phase 2b ACCESS study revealed a placebo-adjusted mean weight loss of 11.3% at a 120 mg dose over 36 weeks, while the exploratory ACCESS II study showed an even higher placebo-adjusted mean weight loss of 15.3% at a 240 mg dose. These promising results have drawn attention from several analyst firms. Stifel reiterated a Buy rating with a $50.00 price target, emphasizing the importance of the trial data for the company’s portfolio. Similarly, H.C. Wainwright maintained a Buy rating with a $60.00 price target, focusing on the drug’s comparison with other weight loss treatments. Citizens also maintained its Market Outperform rating and set a price target of $87.00, noting the stock’s steady climb since August. BMO Capital reiterated an Outperform rating with a $100.00 price target, highlighting the significance of the upcoming trial data for aleniglipron’s market positioning. These developments reflect continued optimism among analysts regarding Structure Therapeutics’ future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.